nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR2C—Sorafenib—liver cancer	0.257	0.458	CbGbCtD
Atomoxetine—CYP2C19—Sorafenib—liver cancer	0.101	0.181	CbGbCtD
Atomoxetine—CYP2D6—Sorafenib—liver cancer	0.077	0.137	CbGbCtD
Atomoxetine—CYP3A4—Sorafenib—liver cancer	0.0489	0.0874	CbGbCtD
Atomoxetine—CYP2D6—Doxorubicin—liver cancer	0.0467	0.0834	CbGbCtD
Atomoxetine—CYP3A4—Doxorubicin—liver cancer	0.0297	0.053	CbGbCtD
Atomoxetine—Gastrointestinal symptom NOS—Sorafenib—liver cancer	0.00703	0.0282	CcSEcCtD
Atomoxetine—Completed suicide—Sorafenib—liver cancer	0.00703	0.0282	CcSEcCtD
Atomoxetine—Oropharyngeal discomfort—Sorafenib—liver cancer	0.00569	0.0228	CcSEcCtD
Atomoxetine—Rhinorrhoea—Sorafenib—liver cancer	0.0051	0.0205	CcSEcCtD
Atomoxetine—Bone disorder—Sorafenib—liver cancer	0.00458	0.0184	CcSEcCtD
Atomoxetine—Drug interaction—Sorafenib—liver cancer	0.00446	0.0179	CcSEcCtD
Atomoxetine—Blood pressure increased—Sorafenib—liver cancer	0.00414	0.0166	CcSEcCtD
Atomoxetine—Sinus tachycardia—Epirubicin—liver cancer	0.00379	0.0152	CcSEcCtD
Atomoxetine—Pseudoephedrine—IL2—liver cancer	0.00351	0.32	CrCbGaD
Atomoxetine—Sinus tachycardia—Doxorubicin—liver cancer	0.00351	0.0141	CcSEcCtD
Atomoxetine—Hepatic failure—Sorafenib—liver cancer	0.00334	0.0134	CcSEcCtD
Atomoxetine—Mood swings—Sorafenib—liver cancer	0.00284	0.0114	CcSEcCtD
Atomoxetine—Abdominal pain upper—Sorafenib—liver cancer	0.00274	0.011	CcSEcCtD
Atomoxetine—Breast disorder—Sorafenib—liver cancer	0.00271	0.0109	CcSEcCtD
Atomoxetine—Nasopharyngitis—Sorafenib—liver cancer	0.00268	0.0108	CcSEcCtD
Atomoxetine—Pelvic pain—Epirubicin—liver cancer	0.00251	0.0101	CcSEcCtD
Atomoxetine—Abdominal discomfort—Sorafenib—liver cancer	0.00249	0.00997	CcSEcCtD
Atomoxetine—Erectile dysfunction—Sorafenib—liver cancer	0.00239	0.00958	CcSEcCtD
Atomoxetine—Weight decreased—Sorafenib—liver cancer	0.00235	0.00941	CcSEcCtD
Atomoxetine—Pelvic pain—Doxorubicin—liver cancer	0.00232	0.00932	CcSEcCtD
Atomoxetine—Infestation NOS—Sorafenib—liver cancer	0.00231	0.00928	CcSEcCtD
Atomoxetine—Infestation—Sorafenib—liver cancer	0.00231	0.00928	CcSEcCtD
Atomoxetine—Urinary tract disorder—Sorafenib—liver cancer	0.00205	0.00822	CcSEcCtD
Atomoxetine—Urethral disorder—Sorafenib—liver cancer	0.00204	0.00816	CcSEcCtD
Atomoxetine—Flushing—Sorafenib—liver cancer	0.00193	0.00773	CcSEcCtD
Atomoxetine—Cardiac disorder—Sorafenib—liver cancer	0.00193	0.00773	CcSEcCtD
Atomoxetine—Angiopathy—Sorafenib—liver cancer	0.00188	0.00755	CcSEcCtD
Atomoxetine—Rigors—Epirubicin—liver cancer	0.00187	0.00751	CcSEcCtD
Atomoxetine—Mediastinal disorder—Sorafenib—liver cancer	0.00187	0.0075	CcSEcCtD
Atomoxetine—Mental disorder—Sorafenib—liver cancer	0.00182	0.00729	CcSEcCtD
Atomoxetine—Malnutrition—Sorafenib—liver cancer	0.00181	0.00725	CcSEcCtD
Atomoxetine—Delirium—Epirubicin—liver cancer	0.00178	0.00712	CcSEcCtD
Atomoxetine—Dysgeusia—Sorafenib—liver cancer	0.00177	0.0071	CcSEcCtD
Atomoxetine—Muscle spasms—Sorafenib—liver cancer	0.00174	0.00697	CcSEcCtD
Atomoxetine—Rigors—Doxorubicin—liver cancer	0.00173	0.00694	CcSEcCtD
Atomoxetine—Bone disorder—Epirubicin—liver cancer	0.00169	0.00678	CcSEcCtD
Atomoxetine—Delirium—Doxorubicin—liver cancer	0.00164	0.00659	CcSEcCtD
Atomoxetine—Syncope—Sorafenib—liver cancer	0.00162	0.0065	CcSEcCtD
Atomoxetine—Loss of consciousness—Sorafenib—liver cancer	0.00159	0.00637	CcSEcCtD
Atomoxetine—Cough—Sorafenib—liver cancer	0.00158	0.00632	CcSEcCtD
Atomoxetine—Bone disorder—Doxorubicin—liver cancer	0.00157	0.00628	CcSEcCtD
Atomoxetine—Arthralgia—Sorafenib—liver cancer	0.00154	0.00617	CcSEcCtD
Atomoxetine—Myalgia—Sorafenib—liver cancer	0.00154	0.00617	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00153	0.00613	CcSEcCtD
Atomoxetine—Abnormal dreams—Epirubicin—liver cancer	0.00151	0.00606	CcSEcCtD
Atomoxetine—Dry mouth—Sorafenib—liver cancer	0.00151	0.00604	CcSEcCtD
Atomoxetine—Infection—Sorafenib—liver cancer	0.00147	0.00588	CcSEcCtD
Atomoxetine—Shock—Sorafenib—liver cancer	0.00145	0.00582	CcSEcCtD
Atomoxetine—Nervous system disorder—Sorafenib—liver cancer	0.00145	0.0058	CcSEcCtD
Atomoxetine—Skin disorder—Sorafenib—liver cancer	0.00143	0.00575	CcSEcCtD
Atomoxetine—Anorexia—Sorafenib—liver cancer	0.00141	0.00564	CcSEcCtD
Atomoxetine—Abnormal dreams—Doxorubicin—liver cancer	0.0014	0.0056	CcSEcCtD
Atomoxetine—Coma—Epirubicin—liver cancer	0.0014	0.0056	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00134	0.00539	CcSEcCtD
Atomoxetine—Dyspepsia—Sorafenib—liver cancer	0.0013	0.00521	CcSEcCtD
Atomoxetine—Coma—Doxorubicin—liver cancer	0.00129	0.00518	CcSEcCtD
Atomoxetine—Decreased appetite—Sorafenib—liver cancer	0.00128	0.00514	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00127	0.00511	CcSEcCtD
Atomoxetine—Fatigue—Sorafenib—liver cancer	0.00127	0.0051	CcSEcCtD
Atomoxetine—Pain—Sorafenib—liver cancer	0.00126	0.00506	CcSEcCtD
Atomoxetine—Constipation—Sorafenib—liver cancer	0.00126	0.00506	CcSEcCtD
Atomoxetine—Hepatic failure—Epirubicin—liver cancer	0.00123	0.00495	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Sorafenib—liver cancer	0.00121	0.00484	CcSEcCtD
Atomoxetine—Hot flush—Epirubicin—liver cancer	0.00119	0.00475	CcSEcCtD
Atomoxetine—Pseudoephedrine—TNF—liver cancer	0.00119	0.108	CrCbGaD
Atomoxetine—Menopausal symptoms—Epirubicin—liver cancer	0.00118	0.00471	CcSEcCtD
Atomoxetine—Urticaria—Sorafenib—liver cancer	0.00117	0.0047	CcSEcCtD
Atomoxetine—Body temperature increased—Sorafenib—liver cancer	0.00117	0.00468	CcSEcCtD
Atomoxetine—Abdominal pain—Sorafenib—liver cancer	0.00117	0.00468	CcSEcCtD
Atomoxetine—Hepatic failure—Doxorubicin—liver cancer	0.00114	0.00458	CcSEcCtD
Atomoxetine—Lethargy—Epirubicin—liver cancer	0.00113	0.00454	CcSEcCtD
Atomoxetine—Hot flush—Doxorubicin—liver cancer	0.0011	0.0044	CcSEcCtD
Atomoxetine—Affect lability—Epirubicin—liver cancer	0.00109	0.00438	CcSEcCtD
Atomoxetine—Menopausal symptoms—Doxorubicin—liver cancer	0.00109	0.00436	CcSEcCtD
Atomoxetine—Asthenia—Sorafenib—liver cancer	0.00106	0.00424	CcSEcCtD
Atomoxetine—Mood swings—Epirubicin—liver cancer	0.00105	0.00421	CcSEcCtD
Atomoxetine—Lethargy—Doxorubicin—liver cancer	0.00105	0.0042	CcSEcCtD
Atomoxetine—Pruritus—Sorafenib—liver cancer	0.00104	0.00419	CcSEcCtD
Atomoxetine—Abdominal pain upper—Epirubicin—liver cancer	0.00101	0.00406	CcSEcCtD
Atomoxetine—Affect lability—Doxorubicin—liver cancer	0.00101	0.00405	CcSEcCtD
Atomoxetine—Diarrhoea—Sorafenib—liver cancer	0.00101	0.00405	CcSEcCtD
Atomoxetine—Breast disorder—Epirubicin—liver cancer	0.001	0.00402	CcSEcCtD
Atomoxetine—Nasopharyngitis—Epirubicin—liver cancer	0.000992	0.00398	CcSEcCtD
Atomoxetine—Dizziness—Sorafenib—liver cancer	0.000976	0.00391	CcSEcCtD
Atomoxetine—Mood swings—Doxorubicin—liver cancer	0.000972	0.0039	CcSEcCtD
Atomoxetine—Influenza—Epirubicin—liver cancer	0.000959	0.00384	CcSEcCtD
Atomoxetine—Warfarin—CYP1A1—liver cancer	0.000946	0.0861	CrCbGaD
Atomoxetine—Vomiting—Sorafenib—liver cancer	0.000938	0.00376	CcSEcCtD
Atomoxetine—Abdominal pain upper—Doxorubicin—liver cancer	0.000938	0.00376	CcSEcCtD
Atomoxetine—Rash—Sorafenib—liver cancer	0.00093	0.00373	CcSEcCtD
Atomoxetine—Dermatitis—Sorafenib—liver cancer	0.000929	0.00373	CcSEcCtD
Atomoxetine—Breast disorder—Doxorubicin—liver cancer	0.000928	0.00372	CcSEcCtD
Atomoxetine—Headache—Sorafenib—liver cancer	0.000924	0.00371	CcSEcCtD
Atomoxetine—Nasopharyngitis—Doxorubicin—liver cancer	0.000918	0.00368	CcSEcCtD
Atomoxetine—Dysuria—Epirubicin—liver cancer	0.000897	0.00359	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Epirubicin—liver cancer	0.000891	0.00357	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—liver cancer	0.000887	0.00356	CcSEcCtD
Atomoxetine—Pollakiuria—Epirubicin—liver cancer	0.000886	0.00355	CcSEcCtD
Atomoxetine—Nausea—Sorafenib—liver cancer	0.000876	0.00351	CcSEcCtD
Atomoxetine—Weight decreased—Epirubicin—liver cancer	0.000867	0.00348	CcSEcCtD
Atomoxetine—Infestation NOS—Epirubicin—liver cancer	0.000855	0.00343	CcSEcCtD
Atomoxetine—Infestation—Epirubicin—liver cancer	0.000855	0.00343	CcSEcCtD
Atomoxetine—Conjunctivitis—Epirubicin—liver cancer	0.000831	0.00333	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—liver cancer	0.00083	0.00333	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000825	0.00331	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—liver cancer	0.00082	0.00329	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—liver cancer	0.000803	0.00322	CcSEcCtD
Atomoxetine—Sinusitis—Epirubicin—liver cancer	0.000802	0.00322	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—liver cancer	0.000791	0.00317	CcSEcCtD
Atomoxetine—Infestation NOS—Doxorubicin—liver cancer	0.000791	0.00317	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—liver cancer	0.000769	0.00308	CcSEcCtD
Atomoxetine—Hypoaesthesia—Epirubicin—liver cancer	0.000764	0.00306	CcSEcCtD
Atomoxetine—Urinary tract disorder—Epirubicin—liver cancer	0.000758	0.00304	CcSEcCtD
Atomoxetine—Urethral disorder—Epirubicin—liver cancer	0.000752	0.00302	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—liver cancer	0.000742	0.00298	CcSEcCtD
Atomoxetine—Cardiac disorder—Epirubicin—liver cancer	0.000712	0.00286	CcSEcCtD
Atomoxetine—Flushing—Epirubicin—liver cancer	0.000712	0.00286	CcSEcCtD
Atomoxetine—Hypoaesthesia—Doxorubicin—liver cancer	0.000707	0.00283	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—liver cancer	0.000701	0.00281	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—liver cancer	0.000696	0.00279	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—liver cancer	0.000696	0.00279	CcSEcCtD
Atomoxetine—Mediastinal disorder—Epirubicin—liver cancer	0.000692	0.00277	CcSEcCtD
Atomoxetine—Chills—Epirubicin—liver cancer	0.000689	0.00276	CcSEcCtD
Atomoxetine—Fenoprofen—ALB—liver cancer	0.000689	0.0627	CrCbGaD
Atomoxetine—Mental disorder—Epirubicin—liver cancer	0.000672	0.0027	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—liver cancer	0.000668	0.00268	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—liver cancer	0.000659	0.00264	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—liver cancer	0.000659	0.00264	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—liver cancer	0.000658	0.00264	CcSEcCtD
Atomoxetine—Tension—Epirubicin—liver cancer	0.000656	0.00263	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—liver cancer	0.000654	0.00262	CcSEcCtD
Atomoxetine—Nervousness—Epirubicin—liver cancer	0.000649	0.0026	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—liver cancer	0.000646	0.00259	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—liver cancer	0.000644	0.00258	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—liver cancer	0.000642	0.00258	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—liver cancer	0.00064	0.00257	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—liver cancer	0.000637	0.00255	CcSEcCtD
Atomoxetine—Propranolol—CYP1A1—liver cancer	0.000633	0.0576	CrCbGaD
Atomoxetine—Vision blurred—Epirubicin—liver cancer	0.00063	0.00252	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—liver cancer	0.000622	0.00249	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—liver cancer	0.000618	0.00248	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—liver cancer	0.000614	0.00246	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—liver cancer	0.000609	0.00244	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—liver cancer	0.000607	0.00243	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—liver cancer	0.000605	0.00243	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—liver cancer	0.0006	0.00241	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—liver cancer	0.0006	0.00241	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—liver cancer	0.000599	0.0024	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—liver cancer	0.000598	0.0024	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—liver cancer	0.000594	0.00238	CcSEcCtD
Atomoxetine—Phenprocoumon—ALB—liver cancer	0.000594	0.054	CrCbGaD
Atomoxetine—Palpitations—Epirubicin—liver cancer	0.00059	0.00237	CcSEcCtD
Atomoxetine—Nortriptyline—CYP2E1—liver cancer	0.00059	0.0537	CrCbGaD
Atomoxetine—Loss of consciousness—Epirubicin—liver cancer	0.000587	0.00235	CcSEcCtD
Atomoxetine—Cough—Epirubicin—liver cancer	0.000583	0.00234	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—liver cancer	0.000583	0.00234	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—liver cancer	0.000579	0.00232	CcSEcCtD
Atomoxetine—Fluoxetine—ALB—liver cancer	0.000578	0.0526	CrCbGaD
Atomoxetine—Chest pain—Epirubicin—liver cancer	0.000569	0.00228	CcSEcCtD
Atomoxetine—Arthralgia—Epirubicin—liver cancer	0.000569	0.00228	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—liver cancer	0.000569	0.00228	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—liver cancer	0.000568	0.00228	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—liver cancer	0.000567	0.00227	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000565	0.00226	CcSEcCtD
Atomoxetine—Dry mouth—Epirubicin—liver cancer	0.000556	0.00223	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—liver cancer	0.000555	0.00223	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—liver cancer	0.000554	0.00222	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—liver cancer	0.000546	0.00219	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—liver cancer	0.000543	0.00218	CcSEcCtD
Atomoxetine—Infection—Epirubicin—liver cancer	0.000542	0.00217	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—liver cancer	0.000539	0.00216	CcSEcCtD
Atomoxetine—Shock—Epirubicin—liver cancer	0.000536	0.00215	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—liver cancer	0.000536	0.00215	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—liver cancer	0.000535	0.00214	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—liver cancer	0.000532	0.00213	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—liver cancer	0.00053	0.00212	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—liver cancer	0.000527	0.00211	CcSEcCtD
Atomoxetine—Warfarin—ALB—liver cancer	0.000527	0.0479	CrCbGaD
Atomoxetine—Arthralgia—Doxorubicin—liver cancer	0.000526	0.00211	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—liver cancer	0.000526	0.00211	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—liver cancer	0.000526	0.00211	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—liver cancer	0.000524	0.0021	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000523	0.0021	CcSEcCtD
Atomoxetine—Anorexia—Epirubicin—liver cancer	0.00052	0.00208	CcSEcCtD
Atomoxetine—Orphenadrine—CYP2E1—liver cancer	0.000516	0.047	CrCbGaD
Atomoxetine—Dry mouth—Doxorubicin—liver cancer	0.000515	0.00206	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—liver cancer	0.000501	0.00201	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000497	0.00199	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—liver cancer	0.000496	0.00199	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—liver cancer	0.000495	0.00198	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—liver cancer	0.000493	0.00198	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—liver cancer	0.000492	0.00197	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—liver cancer	0.00049	0.00196	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—liver cancer	0.00049	0.00196	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—liver cancer	0.000488	0.00196	CcSEcCtD
Atomoxetine—Desipramine—CYP2E1—liver cancer	0.000486	0.0442	CrCbGaD
Atomoxetine—Somnolence—Epirubicin—liver cancer	0.000485	0.00194	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—liver cancer	0.000481	0.00193	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—liver cancer	0.00048	0.00192	CcSEcCtD
Atomoxetine—Decreased appetite—Epirubicin—liver cancer	0.000474	0.0019	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000471	0.00189	CcSEcCtD
Atomoxetine—Fatigue—Epirubicin—liver cancer	0.00047	0.00188	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—liver cancer	0.000466	0.00187	CcSEcCtD
Atomoxetine—Pain—Epirubicin—liver cancer	0.000466	0.00187	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00046	0.00184	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—liver cancer	0.000456	0.00183	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—liver cancer	0.000453	0.00182	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—liver cancer	0.000449	0.0018	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—liver cancer	0.000449	0.0018	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—liver cancer	0.000446	0.00179	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—liver cancer	0.000444	0.00178	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—liver cancer	0.000439	0.00176	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000436	0.00175	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—liver cancer	0.000435	0.00174	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—liver cancer	0.000433	0.00174	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—liver cancer	0.000431	0.00173	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—liver cancer	0.000431	0.00173	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—liver cancer	0.000431	0.00173	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—liver cancer	0.000431	0.00173	CcSEcCtD
Atomoxetine—Feeling abnormal—Doxorubicin—liver cancer	0.000416	0.00167	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000413	0.00165	CcSEcCtD
Atomoxetine—Ketoprofen—ALB—liver cancer	0.000406	0.037	CrCbGaD
Atomoxetine—Urticaria—Doxorubicin—liver cancer	0.000401	0.00161	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—liver cancer	0.000399	0.0016	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—liver cancer	0.000399	0.0016	CcSEcCtD
Atomoxetine—Asthenia—Epirubicin—liver cancer	0.000391	0.00157	CcSEcCtD
Atomoxetine—Pruritus—Epirubicin—liver cancer	0.000386	0.00155	CcSEcCtD
Atomoxetine—Diarrhoea—Epirubicin—liver cancer	0.000373	0.0015	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—liver cancer	0.000362	0.00145	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—liver cancer	0.000361	0.00145	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—liver cancer	0.000357	0.00143	CcSEcCtD
Atomoxetine—Vomiting—Epirubicin—liver cancer	0.000347	0.00139	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—liver cancer	0.000345	0.00138	CcSEcCtD
Atomoxetine—Rash—Epirubicin—liver cancer	0.000344	0.00138	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—liver cancer	0.000343	0.00138	CcSEcCtD
Atomoxetine—Headache—Epirubicin—liver cancer	0.000342	0.00137	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—liver cancer	0.000334	0.00134	CcSEcCtD
Atomoxetine—Nortriptyline—ALB—liver cancer	0.000324	0.0295	CrCbGaD
Atomoxetine—Nausea—Epirubicin—liver cancer	0.000324	0.0013	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—liver cancer	0.000321	0.00129	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—liver cancer	0.000318	0.00128	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—liver cancer	0.000318	0.00127	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—liver cancer	0.000316	0.00127	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—liver cancer	0.0003	0.0012	CcSEcCtD
Atomoxetine—HTR6—Signaling Pathways—BRAF—liver cancer	3.3e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BRAF—liver cancer	3.28e-05	0.000183	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GOT2—liver cancer	3.27e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CB—liver cancer	3.21e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BRAF—liver cancer	3.21e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—liver cancer	3.2e-05	0.000179	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PSMA4—liver cancer	3.09e-05	0.000173	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PSMD10—liver cancer	3.09e-05	0.000173	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CD—liver cancer	3.09e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—liver cancer	3.08e-05	0.000172	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2E1—liver cancer	3.08e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TERT—liver cancer	3.07e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CD—liver cancer	3.06e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PIK3CA—liver cancer	3.06e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—liver cancer	3.05e-05	0.00017	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTA4—liver cancer	3.05e-05	0.00017	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PIK3CA—liver cancer	3.03e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—liver cancer	3.03e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KRAS—liver cancer	3.02e-05	0.000169	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GOT2—liver cancer	3.01e-05	0.000168	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CD—liver cancer	3e-05	0.000167	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KRAS—liver cancer	3e-05	0.000167	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CSF2—liver cancer	2.99e-05	0.000167	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RAF1—liver cancer	2.98e-05	0.000166	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.98e-05	0.000166	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTA2—liver cancer	2.98e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PIK3CA—liver cancer	2.97e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—liver cancer	2.97e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—H2AFX—liver cancer	2.95e-05	0.000164	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—liver cancer	2.95e-05	0.000164	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KRAS—liver cancer	2.94e-05	0.000164	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CB—liver cancer	2.91e-05	0.000163	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYCS—liver cancer	2.88e-05	0.000161	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTA1—liver cancer	2.87e-05	0.00016	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NAT2—liver cancer	2.84e-05	0.000158	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2E1—liver cancer	2.83e-05	0.000158	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GOT1—liver cancer	2.82e-05	0.000158	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GGT1—liver cancer	2.82e-05	0.000158	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KDR—liver cancer	2.81e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK14—liver cancer	2.79e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PIK3CA—liver cancer	2.78e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RAF1—liver cancer	2.76e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PIK3CA—liver cancer	2.76e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ESR1—liver cancer	2.74e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RAF1—liver cancer	2.74e-05	0.000153	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDOB—liver cancer	2.72e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—F2—liver cancer	2.7e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PIK3CA—liver cancer	2.7e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CB—liver cancer	2.69e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MTOR—liver cancer	2.69e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RAF1—liver cancer	2.68e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—liver cancer	2.68e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MTOR—liver cancer	2.67e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CB—liver cancer	2.67e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TERT—liver cancer	2.67e-05	0.000149	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYCS—liver cancer	2.65e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CB—liver cancer	2.61e-05	0.000146	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MTOR—liver cancer	2.61e-05	0.000146	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GGT1—liver cancer	2.6e-05	0.000145	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GOT1—liver cancer	2.6e-05	0.000145	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CRABP1—liver cancer	2.6e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—liver cancer	2.59e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APC—liver cancer	2.59e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—liver cancer	2.57e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—liver cancer	2.55e-05	0.000142	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—liver cancer	2.54e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1B—liver cancer	2.53e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1B—liver cancer	2.51e-05	0.00014	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—liver cancer	2.5e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—liver cancer	2.5e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—liver cancer	2.5e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—liver cancer	2.48e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—liver cancer	2.48e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—liver cancer	2.47e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—liver cancer	2.46e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—liver cancer	2.46e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1B—liver cancer	2.45e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—liver cancer	2.45e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—liver cancer	2.44e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KDR—liver cancer	2.44e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—liver cancer	2.43e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—liver cancer	2.43e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK14—liver cancer	2.42e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—liver cancer	2.41e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—liver cancer	2.41e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—JUN—liver cancer	2.4e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—liver cancer	2.4e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—liver cancer	2.39e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—liver cancer	2.39e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—JUN—liver cancer	2.39e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CTNNB1—liver cancer	2.39e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ESR1—liver cancer	2.38e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CTNNB1—liver cancer	2.37e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—F2—liver cancer	2.35e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—liver cancer	2.34e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—liver cancer	2.34e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JUN—liver cancer	2.34e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—liver cancer	2.33e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—liver cancer	2.33e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1A—liver cancer	2.33e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—liver cancer	2.32e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CTNNB1—liver cancer	2.32e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1A—liver cancer	2.31e-05	0.000129	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—liver cancer	2.3e-05	0.000128	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK8—liver cancer	2.27e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CD—liver cancer	2.27e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—liver cancer	2.27e-05	0.000127	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HPGDS—liver cancer	2.27e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—liver cancer	2.27e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1A—liver cancer	2.26e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK8—liver cancer	2.26e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—liver cancer	2.25e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—liver cancer	2.25e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—liver cancer	2.25e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—liver cancer	2.25e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—liver cancer	2.25e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—liver cancer	2.23e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK8—liver cancer	2.21e-05	0.000123	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A1—liver cancer	2.21e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—liver cancer	2.2e-05	0.000123	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—liver cancer	2.14e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—liver cancer	2.11e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—liver cancer	2.1e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—liver cancer	2.08e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—liver cancer	2.08e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—liver cancer	2.06e-05	0.000115	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—liver cancer	2.06e-05	0.000115	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	2.05e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—liver cancer	2.04e-05	0.000114	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A1—liver cancer	2.03e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RAF1—liver cancer	2.03e-05	0.000113	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PSMA4—liver cancer	2.02e-05	0.000113	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PSMD10—liver cancer	2.02e-05	0.000113	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARA—liver cancer	2.02e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—liver cancer	2.02e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CB—liver cancer	1.98e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MTOR—liver cancer	1.98e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CD—liver cancer	1.97e-05	0.00011	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GOT2—liver cancer	1.97e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	1.96e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—liver cancer	1.95e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—liver cancer	1.93e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—liver cancer	1.93e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—liver cancer	1.93e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—liver cancer	1.92e-05	0.000107	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—liver cancer	1.91e-05	0.000107	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—liver cancer	1.9e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—liver cancer	1.89e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—liver cancer	1.88e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—liver cancer	1.87e-05	0.000104	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1B—liver cancer	1.86e-05	0.000104	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARA—liver cancer	1.86e-05	0.000104	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2E1—liver cancer	1.85e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—liver cancer	1.84e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—liver cancer	1.82e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—liver cancer	1.82e-05	0.000102	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.82e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—liver cancer	1.81e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—liver cancer	1.79e-05	9.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	1.78e-05	9.91e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—liver cancer	1.77e-05	9.9e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—liver cancer	1.77e-05	9.88e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUN—liver cancer	1.77e-05	9.88e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RAF1—liver cancer	1.76e-05	9.83e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CTNNB1—liver cancer	1.76e-05	9.8e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—liver cancer	1.74e-05	9.68e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—liver cancer	1.73e-05	9.66e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYCS—liver cancer	1.73e-05	9.66e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—liver cancer	1.72e-05	9.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MTOR—liver cancer	1.72e-05	9.6e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CB—liver cancer	1.72e-05	9.6e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.72e-05	9.57e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GOT1—liver cancer	1.7e-05	9.47e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GGT1—liver cancer	1.7e-05	9.47e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.68e-05	9.34e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—liver cancer	1.67e-05	9.32e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.67e-05	9.32e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—liver cancer	1.64e-05	9.16e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—liver cancer	1.64e-05	9.15e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—liver cancer	1.63e-05	9.08e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1B—liver cancer	1.61e-05	9.01e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—liver cancer	1.6e-05	8.91e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—liver cancer	1.59e-05	8.89e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—liver cancer	1.59e-05	8.88e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—liver cancer	1.59e-05	8.85e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—liver cancer	1.58e-05	8.83e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—liver cancer	1.58e-05	8.82e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—liver cancer	1.57e-05	8.79e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—liver cancer	1.57e-05	8.77e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.55e-05	8.63e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—liver cancer	1.54e-05	8.6e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—liver cancer	1.54e-05	8.59e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUN—liver cancer	1.54e-05	8.58e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—liver cancer	1.54e-05	8.57e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—liver cancer	1.53e-05	8.54e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	1.53e-05	8.51e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—liver cancer	1.53e-05	8.51e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CD—liver cancer	1.52e-05	8.49e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—liver cancer	1.52e-05	8.47e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—liver cancer	1.51e-05	8.4e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—liver cancer	1.5e-05	8.39e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—liver cancer	1.5e-05	8.38e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—liver cancer	1.5e-05	8.34e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	1.49e-05	8.31e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—liver cancer	1.47e-05	8.23e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK8—liver cancer	1.45e-05	8.11e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—liver cancer	1.45e-05	8.1e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—liver cancer	1.45e-05	8.09e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—liver cancer	1.44e-05	8.04e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—liver cancer	1.42e-05	7.94e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—liver cancer	1.42e-05	7.92e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—liver cancer	1.41e-05	7.87e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—liver cancer	1.4e-05	7.82e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CD—liver cancer	1.4e-05	7.81e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—liver cancer	1.38e-05	7.71e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—liver cancer	1.34e-05	7.49e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—liver cancer	1.34e-05	7.48e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—liver cancer	1.33e-05	7.42e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—liver cancer	1.33e-05	7.42e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A1—liver cancer	1.33e-05	7.41e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CB—liver cancer	1.33e-05	7.4e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—liver cancer	1.31e-05	7.33e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—liver cancer	1.3e-05	7.26e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—liver cancer	1.24e-05	6.91e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—liver cancer	1.24e-05	6.89e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—liver cancer	1.23e-05	6.88e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CB—liver cancer	1.22e-05	6.81e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARA—liver cancer	1.22e-05	6.78e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	1.21e-05	6.74e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—liver cancer	1.17e-05	6.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—liver cancer	1.14e-05	6.37e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—liver cancer	1.12e-05	6.23e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—liver cancer	1.07e-05	5.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	1.05e-05	5.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—liver cancer	1.04e-05	5.81e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—liver cancer	1.01e-05	5.66e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—liver cancer	1e-05	5.6e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—liver cancer	9.87e-06	5.51e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—liver cancer	9.71e-06	5.41e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—liver cancer	9.29e-06	5.18e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CD—liver cancer	9.15e-06	5.11e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—liver cancer	9.03e-06	5.04e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—liver cancer	8.57e-06	4.78e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—liver cancer	8.09e-06	4.51e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CB—liver cancer	7.98e-06	4.45e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—liver cancer	7.44e-06	4.15e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—liver cancer	6.61e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—liver cancer	6.08e-06	3.39e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—liver cancer	4.86e-06	2.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—liver cancer	3.97e-06	2.22e-05	CbGpPWpGaD
